Biohaven Spotlights Nurtec ODT

Published on: 

17 abstracts highlighting safety and efficacy to be shared at upcoming conference.

Biohaven Pharmaceutical Holding Company Ltd. today announced that 17 abstracts, including three late-breaking presentations and four oral presentations, will be shared at the 2021 International Headache Society–European Headache Federation Joint Congress virtually from September 8-12, 2021.

Biohaven will be presenting most recent data for its migraine portfolio including Nurtec® ODT (rimegepant) orally dissolving tablets 75 mg, the first and only calcitonin gene-related peptide (CGRP) receptor antagonist in an orally disintegrating tablet (ODT) approved by the FDA for the acute treatment of migraine and the preventive treatment of episodic migraine in adults; and intranasal zavegepant, the only intranasal CGRP receptor antagonist currently in late-stage clinical trials for the acute treatment of migraine.


Read more about the presentation here.